HIMS — Hims & Hers Health, Inc. stock price, charts and financials

NYSE·Healthcare·Medical - Care Facilities·USA

Latest market price

27.99

+0.10+0.36%

Overview Short InterestFilings

HIMSQT35Hims & Hers Health, Inc.·NYSE

Overview Short InterestFilings

27.99+0.36%

Loading chart...

Signal & projected range

Insider selling clusterHistorical pattern — not a prediction

Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)

Horizon

Unlock the projected rangeSee where this setup landed historically — with Premium.

Unlock with Premium

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Unlock with Premium to see the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands of historical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →

CHE-0.38%$504.06 PACS+0.14%$42.12 LFST-0.32%$12.57 CON-0.17%$35.47 ENSG-0.58%$173.91 UHS-2.25%$176.69 OPCH-0.82%$24.30 NHC-1.21%$222.11

Snapshot

Index	-	P/E	-	EPS (ttm)	-0.63	Insider Own	3.22%	Shs Outstand	223.08M	Perf Week	1.74%

Market Cap	6.24B	Forward P/E	93.83	EPS next Y	0.30	Insider Trans	-4.40%	Shs Float	208.82M	Perf Month	-9.97%

Enterprise Value	7.18B	PEG	1.09	EPS next Q	0.08	Inst Own	-	Short Float	26.31%	Perf Quarter	-21.09%

Income	-136.74M	P/S	2.42	EPS this Y	6.46%	Inst Trans	-	Short Ratio	3.53	Perf Half Y	15.85%

Sales	2.58B	P/B	20.02	EPS next Y	150.62%	ROA	-3.91%	Short Interest	54.95M	Perf YTD	-13.80%

Book/sh	-	P/C	24.31	EPS next 5Y	-	ROE	-30.03%	52W High	65.31 -57.14%	Perf Year	-44.41%

Cash/sh	-	P/FCF	69.47	EPS past 3/5Y	-	ROIC	-3.73%	52W Low	13.74 103.71%	Perf 3Y	340.09%

Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	64.55% 73.58%	Gross Margin	64.68%	Volatility	5.25% 5.37%	Perf 5Y	221.35%

Dividend TTM	-	EV/Sales	2.79	EPS Y/Y TTM	-218.87%	Oper. Margin	-3.59%	ATR (14)	1.65	Perf 10Y	-

Dividend Ex-Date	-	Quick Ratio	0.87	Sales Y/Y TTM	74.54%	Profit Margin	-5.51%	RSI (14)	45.59	Recom	2.65

Dividend Gr. 3/5Y	-	Current Ratio	0.93	EPS Q/Q	-317.65%	SMA20	-3.60%	Beta	2.42	Target Price	32.17

Payout	0.00%	Debt/Eq	4.77	Sales Q/Q	38.17%	SMA50	-7.30%	Rel Volume	0.71	Prev Close	27.89

Employees	2,442	LT Debt/Eq	2.06	Earnings	Nov 09	SMA200	0.03%	Avg Volume	13.19M	Price	27.99

IPO Date	Sep 13, 2019	Option/Short	Yes / Yes	EPS/Sales Surpr.	-643.15% 7.77%	Net Debt/EBITDA	-12.25	Volume	9,352,368	Change	0.36%

Analyst Ratings

Date	Action	Analyst	Rating	Target
Aug-24-26	Reiterated	Truist Securities	Hold	$18 → $32
Aug-11-26	Reiterated	Morgan Stanley	Equal Weight	$21 → $28
Aug-11-26	Reiterated	Deutsche Bank	Hold	$25 → $26
Aug-11-26	Reiterated	Needham	Buy	$30 → $42
Jul-09-26	Reiterated	UBS		$25 → $37
Jul-01-26	Reiterated	Canaccord Genuity	Buy	$32 → $40
Jun-02-26	Reiterated	Leerink Partners	Market Perform	$18 → $25
May-26-26	Reiterated	UBS		$23 → $25
May-22-26	Reiterated	UBS		$18 → $23
May-12-26	Reiterated	Jefferies	Hold	$26 → $25

Latest News· Times ET

Sep-18-26

Sep-18-2601:50PM

Robbins LLP Urges HIMS Stockholders Who Lost Money Investing in Hims & Hers Health, Inc. to Contact the Firm for Information About Leading the Class Actionbusinesswire.com

01:00PM

Kaplan Fox Reminds Hims & Hers Health, Inc. (HIMS) Investors to Seek a Leadership Role Before Deadline on November 2, 2026newsfilecorp.com

11:18AM

Hims & Hers Health (NYSE: HIMS) Faces Securities Class Action After FTC Lawsuit Reveal Drives Stock Sharply Lower -- HBSSnewsfilecorp.com

09:25AM

Hims & Hers Health, Inc. (HIMS) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuitprnewswire.com

07:30AM

Kaplan Fox Reminds Hims & Hers Health, Inc. (NYSE: HIMS) Investors of a Securities Class Action Deadline on November 2, 2026globenewswire.com

Sep-17-26

Sep-17-2605:00PM

HIMS INVESTOR DEADLINE: Hims & Hers Health, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit Before November 2, 2026 Deadline, Robbins Geller Rudman & Dowd LLP Annogurufocus.com

04:20PM

02:40PM

Hims & Hers Health (HIMS) Investors with Substantial Losses Have Opportunity to Lead Hims & Hers Class Action Lawsuit Before November 2, 2026 Deadlineprnewswire.com

12:45PM

Kaplan Fox Notifies Investors of Hims & Hers Health, Inc. (HIMS) of the Lead Plaintiff Deadline on November 2, 2026newsfilecorp.com

12:00PM

Hims & Hers Health, Inc. (HIMS) Investors: November 2, 2026, Deadline in Securities Fraud Class Action Lawsuitprnewswire.com

11:31AM

HIMS Investors with Losses in Excess of $100K Have Opportunity to Lead Hims & Hers Health, Inc. Securities Fraud Lawsuitprnewswire.com

08:24AM

Hims & Hers Health Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against Hims & Hers Health, Inc. - HIMSglobenewswire.com

08:00AM

Bronstein, Gewirtz & Grossman LLC Urges Hims & Hers Health, Inc. Investors to Act: Class Action Filed Alleging Investor Harmglobenewswire.com

06:53AM

Faruqi & Faruqi, LLP Urges Hims & Hers Health, Inc. (HIMS) Investors to Seek Counsel Before the November 2, 2026 Lead Plaintiff Deadline in the Securities Class Actionnewsfilecorp.com

06:00AM

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Hims & Hers Health, Inc. of Class Action Lawsuit and Upcoming Deadlines - HIMSprnewswire.com

Company

Hims & Hers Health, Inc. operates a comprehensive digital health platform that seamlessly links individuals with licensed medical professionals for virtual consultations and ongoing care. Through its user-friendly websites and mobile app, the company delivers a diverse portfolio of health and wellness solutions directly to consumers. This includes access to recurring prescription medications, alongside a wide selection of over-the-counter drugs, devices, cosmetics, and dietary supplements. Its core focus areas are general wellness, sexual health, skincare, and hair care. Specific non-prescription offerings span categories such as: Wellness: encompassing items like vitamin C, melatonin, biotin, and collagen protein supplements. Skincare: including products such as moisturizers, serums, and face washes. Sexual Health: providing essentials like condoms, climax delay sprays and wipes, vibrators, and lubricants. Hair Care: offering specialized shampoos, conditioners, scalp scrubs, and topical treatments like minoxidil. Beyond direct sales, Hims & Hers also distributes health and wellness products via wholesale partnerships. The company's headquarters are located in San Francisco, California.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements

DataTimeframe

Line Item (USD, M)	TTM —	FY 2025 12/31/2025	FY 2024 12/31/2024	FY 2023 12/31/2023	FY 2022 12/31/2022	FY 2021 12/31/2021	FY 2020 12/31/2020	FY 2019 12/31/2019
Total Revenue	2,578	2,348	1,477	—	—	—	—	—
Cost of Goods Sold Incl. D&A	910	614	303	—	—	—	—	—
Gross Profit	1,667	1,733	1,173	—	—	—	—	—
Selling, General and Administrative Excl. Other	1,387	1,192	847	—	—	—	—	—
Research and Development	129	149	79	—	—	—	—	—
Other Operating Expense	244	287	185	—	—	—	—	—
Operating Income	-92	106	62	—	—	—	—	—
Interest Expense	0	0	0	—	—	—	—	—
Unusual Expense	—	—	—	—	—	—	—	—
Non-Operating Income (Expense)	-71	18	10	—	—	—	—	—
Net Income Before Taxes	-165	124	72	—	—	—	—	—
Income Taxes	-21	-4	-54	—	—	—	—	—
Consolidated Net Income	-141	128	126	—	—	—	—	—
Net Income From Continuing Operations	-141	128	126	—	—	—	—	—
Net Income	-141	128	126	—	—	—	—	—
EPS (Recurring)	-0.61	0.57	0.58	—	—	—	—	—
EPS (Basic, Before Extraordinaries)	-0.61	0.57	0.58	—	—	—	—	—
EPS (Diluted)	-0.63	0.51	0.53	—	—	—	—	—
EBITDA	-77	178	89	—	—	—	—	—
Other After Tax Adjustments	—	—	—	—	—	—	—	—
Stock Option Compensation Expense	—	—	—	—	—	—	—	—
Price To Earnings Ratio	—	63.67	45.62	—	—	—	—	—
Price To Sales Ratio	2.52	3.11	3.54	—	—	—	—	—
Gross Margin	64.66	73.81	79.42	—	—	—	—	—
Operating Margin	-3.57	4.51	4.20	—	—	—	—	—
Net Margin	-5.47	5.45	8.53	—	—	—	—	—
Shares Outstanding	232	225	216	—	—	—	—	—
Market Capitalization	6,494	7,306	5,223	—	—	—	—	—
Operating Lease Expense	—	—	—	—	—	—	—	—

Unlock full historical data

See years of past statements with Premium.

Unlock with Premium

Insider Trading Volume

Insider Trading

Insider	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Okupe Oluyemi	Chief Financial Officer	Sep 17 '26	Sale	28.82	12,313	354,861	251,804	Sep 18
Boughton Soleil	Chief Legal Officer	Sep 16 '26	Sale	27.86	6,236	173,735	304,270	Sep 17
Elshenawy Mohamed	CTO	Sep 15 '26	Sale	28.39	7,954	225,814	185,556	Sep 17
Chi Michael	Chief Operating Officer	Sep 15 '26	Sale	28.39	14,027	398,227	456,660	Sep 17
Boughton Soleil	Chief Legal Officer	Sep 02 '26	Sale	28.33	3,458	97,965	310,506	Sep 03
Okupe Oluyemi	Chief Financial Officer	Aug 19 '26	Option Exercise	5.01	4,938	24,739	269,055	Aug 20
Boughton Soleil	Chief Legal Officer	Aug 19 '26	Sale	27.55	25,111	691,808	313,964	Aug 20
Okupe Oluyemi	Chief Financial Officer	Aug 19 '26	Sale	29.99	4,938	148,111	264,117	Aug 20
Autor Deborah M.	Chief Policy Officer	Aug 18 '26	Sale	27.85	16,773	467,128	48,961	Aug 20
Okupe Oluyemi	Chief Financial Officer	Aug 17 '26	Sale	27.89	9,388	261,802	264,117	Aug 18
Okupe Oluyemi	Chief Financial Officer	Aug 17 '26	Option Exercise	5.01	9,388	47,034	273,505	Aug 18
Carroll Patrick Harrison	Chief Medical Officer	Aug 14 '26	Option Exercise	0.00	52,114	0	208,048	Aug 18
Dudum Andrew	Chief Executive Officer	Aug 14 '26	Option Exercise	0.00	309,986	0	1,112,036	Aug 18
Chi Michael	Chief Operating Officer	Aug 14 '26	Option Exercise	0.00	172,530	0	518,389	Aug 18
Okupe Oluyemi	Chief Financial Officer	Aug 14 '26	Option Exercise	0.00	143,232	0	300,554	Aug 18

open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR

QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.